Leerink analyst Andrew Berens upgraded Agios Pharmaceuticals (AGIO) to Outperform from Market Perform with a $34 price target
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AGIO:
- Agios Pharmaceuticals price target lowered to $32 from $54 at BofA
- Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories!
- RBC downgrades Agios to Sector Perform after mitapivat ‘falls short’
- Buy Rating Reaffirmed for Agios Pharma’s Mitapivat Amid Promising Trial Results and Safety Profile
- Agios downgraded to Sector Perform from Outperform at RBC Capital